Molnupiravir, the pill against COVID-19 that promises to stop the infection in 24 hours

The United States announced on Wednesday an agreement with the pharmaceutical company Merck to buy 1.7 million treatment lots of an experimental antiviral pill against the COVID-19, if approved by federal authorities.

SIGHT: How long after being immunized against COVID-19 can I receive a different vaccine?

Molnupiravir, which Merck is developing in partnership with Ridgeback Biotherapeutics, is one of several investigational oral antivirals being tested against COVID-19. It is a phase III oral antiviral, which is tested in India and the Philippines, and promises to cut COVID-19 infection in 24 hours.

The drug belongs to a type of antivirals called polymerase inhibitors, which act on an enzyme that viruses need to copy their genetic material by introducing mutations that disable them to replicate.

SIGHT: COVID-19 Vaccines: How Close Are We to Patents Being Lifted?

It has also shown efficacy in laboratory studies against other viruses such as influenza, Ebola, and Venezuelan equine encephalitis, but it has not been licensed or approved for any of these diseases.

In tests for influenza it has been shown to prevent the virus from making copies of itself. According to the researchers, el molnupiravir would prevent the replication machinery of SARS-CoV-2, the virus that causes COVID-19, works and make more copies.

SIGHT: COVID-19 | How do people who are most afraid of getting infected act?

Agreement with the US

The $ 1.2 billion deal is for the drug molnupiravir, currently in phase 3 of a global clinical trial among 1,850 people, with results expected in the autumn.

“This agreement is part of the Biden government-wide approach to developing new COVID-19 treatments and responding to public health needs,” the Department of Health and Human Services said.

READ ALSO:  Top Kremlin Mouthpiece Warns of ‘Inevitable’ War With U.S. Over Another Ukraine Land Grab

The United States will only complete the deal if molnupiravir receives an emergency use authorization or full approval from the Food and Drug Administration (FDA).

Rob Davis, president of Merck, noted that the company “is pleased to collaborate with the United States government on this new agreement that will provide Americans with COVID-19 access to molnupiravir”.

The laboratory expects to have more than 10 million batches available for five treatment days by the end of 2021.

With information from AFP



  • COVID-19 Vaccines: How Close Are We to Patents Being Lifted?
  • COVID-19 | How do people who are most afraid of getting infected act?
  • How long after being immunized against COVID-19 can I receive a different vaccine?
  • Indian variant of coronavirus 40% more contagious, British authorities announce
  • Moderna requests authorization of its vaccine against COVID-19 for adolescents in Europe and Canada
  • Why is India recording so many cases of “black fungus”, the rare condition suffered by recovered COVID-19 patients?
  • The successful case of vaccination in a town in Brazil, by Elmer Huerta
  • Why Mixing and Matching COVID-19 Vaccines Could Solve Many Problems
  • H10N3 Avian Flu: How is it transmitted to humans?
  • The COVID-19 vaccines already approved by the WHO (and how they work)
  • Only one of the lineages of the variant of the coronavirus detected in India is “worrying”
  • What is known about the Wuhan laboratory in China that the United States investigates as a possible origin of the coronavirus
  • Canada approves mixing doses of AstraZeneca and Pfizer vaccines
  • WHO approves emergency use of Chinese coronavirus vaccine Sinovac
  • The “black fungus” and COVID-19: what you should know about this dangerous disease
  • Pfizer’s vaccine works against the Indian variant but its effectiveness is “slightly less”
  • What is known about the new hybrid variant of COVID-19 that is causing an increase in cases in Vietnam
READ ALSO:  Kun Agüero tested positive for coronavirus in antigen testing and negative in PCR

Follow us on twitter:

!function(d,s,id){var js,fjs=d.getElementsByTagName(s)[0],p=/^http:/.test(d.location)?’http’:’https’;if(!d.getElementById(id)){js=d.createElement(s);;js.src=p+’://’;fjs.parentNode.insertBefore(js,fjs);}}(document, ‘script’, ‘twitter-wjs’);


Disclaimer: If you need to update/edit/remove this news or article then please contact our support team Learn more

Leave a Reply